- 503Pharma
- Posts
- 503Pharma. Formula of the Week
503Pharma. Formula of the Week
One formula, torn down — the design choices, the chemistry, and the details that matter at the bench.
503Pharma .
August 12, 2026
STABILITY STUDY CONSORTIUM — FOUNDING MEMBER SPOTS
The 503Pharma Group Stability Study Consortium launches with 20 founding seats at $4,000/year. Membership includes three Category 3 stability studies and extended BUD data you can reference. A single solo study costs more than the full membership.
$4,000/year for at least 3 studies
Limited to 20 founding members
This is the lowest price this program will ever be
See the details and FAQs → or reply to this email and we’ll send enrollment details.
This Week: Testosterone Compounded Cream — 5 mg/g and 100 mg/g
Testosterone Compounded Cream has two reference strengths—5 mg/g (0.5%) and 100 mg/g (10%). The specification defines composition, preparation pathways, assay limits, pH, packaging, storage, labeling, and an NMT (not more than) 90-day BUD at controlled room temperature.
As a DEA Schedule III controlled substance, testosterone carries federal and state registration, inventory, record-keeping, and security requirements. At the bench, the critical steps are: fully wetting the micronized API, dispersing it uniformly, minimizing trapped air, and collecting representative samples.
Component | 5 mg/g (0.5%) | 100 mg/g (10%) |
|---|---|---|
Testosterone, micronized | 0.5 g | 10 g |
Propylene Glycol | 5 mL | 10 mL |
HRT Supreme Cream Base | q.s. 100 g | q.s. 100 g |
Functional roles: testosterone — active androgen (Schedule III); propylene glycol — wetting and levigating agent; HRT Supreme — cream vehicle.
Compounding standard | USP <795> non- sterile |
BUD | NMT 90 days at controlled room temperature—contingent on the specified base, strength, container, and storage |
Container | Tight, light-resistant, suitable calibrated dispenser; store at controlled room temperature |
pH | 5.9–6.9 (USP <791>) |
Assay acceptance | 90.0–110.0% of labeled testosterone by HPLC (UV 245 nm) |
Labeling | External use only; state the beyond-use date |
What’s Worth a Closer Look
1. It’s a dispersed semisolid—and the preparation pathway matters
The formula provides two preparation options: geometric incorporation and electronic mixing with ointment milling. The geometric method adds the cream base in stages, with trituration after each addition. The electronic method uses an electronic mortar and pestle, followed by middle- and fine-setting ointment-mill passes and a final remix. Both begin by wetting micronized testosterone with propylene glycol.
The target is an evenly dispersed, non-gritty cream. To help prevent clumps and uneven drug distribution, thoroughly wet the powder, follow the chosen incorporation sequence, and minimize trapped air. Assay samples must also be collected consistently so the result reflects the batch—not an unusually concentrated or dilute portion of it.
In practice → Choose one pathway and follow it completely. For the geometric method, triturate after each addition. For electronic processing, follow the specified mixing and milling sequence.
2. The two strengths are separate formulas—not a linear scale-up
Testosterone increases twenty-fold (20x) between the formulas, from 0.5 g to 10 g per 100 g, while propylene glycol only doubles. That ratio is specific to these formulas; it does not establish a general rule for how much propylene glycol other strengths require.
Select the intended strength and scale its formula proportionally. Don’t use one formula to calculate the other. Don’t change the propylene glycol amount or substitute a different cream base and still consider it the same preparation. Measure propylene glycol by volume and bring the cream to its final weight.
In practice → Use the strength-specific proportions. If the testosterone is difficult to mix evenly into the cream, check the particle size, wetting step, equipment settings, and mixing process before changing the formula.
3. The 90-day BUD belongs to the specified preparation—not to testosterone generally
The NMT 90-day BUD applies only when a listed strength is prepared with HRT Supreme Cream Base, the prescribed process, a tight, light-resistant calibrated dispenser, and controlled room temperature storage. Changing the base, strength, or container means the reference BUD cannot be carried over without supporting data.
In practice → Treat 90 days as formula-specific. After a material change, assign a new BUD under the applicable USP <795> framework or support it with stability-indicating data for the actual preparation and container.
What’s in the full record
Composition alone does not make a formula executable and defensible. The full record adds master manufacturing instructions, quality-attribute acceptance criteria, in-process controls, release tests, the batch record, and label and BUD language.
Explore the 503Pharma Formula Library
The Testosterone Compounded Cream record includes the composition, example batch, CQAs, equipment, manufacturing instructions, in-process controls, release testing, storage and BUD, controlled-substance and label requirements, and references.
The library holds 100+ sterile and non-sterile formulas built to current USP <795>/<797> standards, with BUD assignments included.
The members area is free to join; formula access is a paid feature.
Disclaimer: This newsletter is provided for educational and informational purposes only and is intended for qualified compounding professionals. It is not medical, legal, regulatory, quality, or other professional advice. All formulas, procedures, specifications, calculations, and beyond-use dates must be independently reviewed and verified against current primary sources, applicable laws and standards, manufacturer information, and the reader’s own professional judgment, policies, equipment, and testing before use.
503Pharma makes no representation or warranty regarding the accuracy, completeness, timeliness, safety, or suitability of this information for any particular purpose. Use of or reliance on this content is solely at the reader’s risk. To the fullest extent permitted by applicable law, 503Pharma and its owners, affiliates, employees, contractors, and authors disclaim liability for any loss, damage, claim, injury, or adverse outcome arising from or related to the use, misuse, or reliance on this content.